Skip to main content
NBP
NASDAQ Life Sciences

NovaBridge Biosciences Doses First Patient in Pivotal Phase 2 Study for Lead Gastric Cancer Drug Givastomig

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$3.457
Mkt Cap
$370.084M
52W Low
$0.595
52W High
$6.79
52W Position info
481% above low
Off High info
49% below high
Rel. Volume info
0.5× avg
Market data snapshot near publication time

NBP has more than doubled off its 52-week low of $0.595.

Summary

NovaBridge Biosciences announced the dosing of the first patient in its global, randomized Phase 2 study for Givastomig, a bispecific antibody for first-line metastatic gastric cancer, marking a critical advancement for its lead oncology candidate.


Key Events · Product Development and Regulatory · NBP

  • Phase 2 Study Initiated for Givastomig

    NovaBridge Biosciences has dosed the first patient in a global, randomized Phase 2 study evaluating Givastomig in combination with immunochemotherapy for first-line metastatic gastric cancer.

  • Builds on Strong Phase 1b Data

    The Phase 2 study follows positive Phase 1b combination data, which demonstrated a 75% objective response rate (ORR) and a median progression-free survival (mPFS) of 16.9 months, positioning Givastomig as a potential best-in-class therapy.

  • Significant Market Opportunity

    Givastomig targets a gastric cancer market projected to reach $12 billion by 2030, highlighting the substantial commercial potential of the drug.

  • Topline Results Expected in 2027

    The company anticipates releasing topline results from the Phase 2 study in 2027, with updated Phase 1b dose expansion data expected in the second half of 2026.


Analysis · NBP · Life Sciences

NovaBridge Biosciences has initiated a global Phase 2 study for Givastomig, its lead bispecific antibody targeting metastatic gastric cancer. This milestone is highly significant as it moves the company's most promising asset into a pivotal stage of clinical development, building on previously reported robust Phase 1b efficacy data. The drug is positioned as a potential best-in-class therapy for a gastric cancer market projected to reach $12 billion by 2030, underscoring its substantial commercial potential. Successful progression in this study could significantly de-risk the asset and drive future valuation.

How filings like this one have moved

In the 30 days to Nov 6, 2026, 45% of the 1400 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.36%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, NBP was trading at $3.46 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $370.1M. The 52-week trading range was $0.60 to $6.79. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

NBP - Latest Insights

NBP
Oct 26, 2026, 6:01 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $1.44
Real-time Price: $0.9068 info
Change: -$0.5288 (-37%) info
Market Cap: $117.159M info
NBP
Oct 25, 2026, 7:00 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $1.42
Real-time Price: $0.9068 info
Change: -$0.5132 (-36%) info
Market Cap: $117.159M info
NBP
Oct 13, 2026, 7:00 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $1.34
Real-time Price: $0.9068 info
Change: -$0.4332 (-32%) info
Market Cap: $117.159M info
NBP
Oct 13, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $1.35
Real-time Price: $0.9068 info
Change: -$0.4432 (-33%) info
Market Cap: $117.159M info
NBP
Aug 20, 2026, 7:00 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $2.02
Real-time Price: $0.9068 info
Change: -$1.11 (-55%) info
Market Cap: $117.159M info